B. Metzler seel. Sohn & Co. AG Has $2.44 Million Holdings in Hologic, Inc. (NASDAQ:HOLX)

B. Metzler seel. Sohn & Co. AG reduced its holdings in shares of Hologic, Inc. (NASDAQ:HOLX - Free Report) by 12.7% during the 4th quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 33,892 shares of the medical equipment provider's stock after selling 4,946 shares during the period. B. Metzler seel. Sohn & Co. AG's holdings in Hologic were worth $2,443,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds have also added to or reduced their stakes in HOLX. Brooklyn Investment Group grew its stake in shares of Hologic by 14.7% in the 4th quarter. Brooklyn Investment Group now owns 1,131 shares of the medical equipment provider's stock valued at $82,000 after purchasing an additional 145 shares during the period. Smartleaf Asset Management LLC grew its holdings in shares of Hologic by 36.9% in the 4th quarter. Smartleaf Asset Management LLC now owns 590 shares of the medical equipment provider's stock worth $43,000 after purchasing an additional 159 shares during the last quarter. Trivant Custom Portfolio Group LLC lifted its holdings in Hologic by 2.1% during the 4th quarter. Trivant Custom Portfolio Group LLC now owns 8,348 shares of the medical equipment provider's stock valued at $602,000 after purchasing an additional 169 shares during the last quarter. UMB Bank n.a. boosted its position in Hologic by 4.1% in the fourth quarter. UMB Bank n.a. now owns 4,758 shares of the medical equipment provider's stock valued at $343,000 after buying an additional 188 shares in the last quarter. Finally, Capital Investment Counsel Inc grew its stake in Hologic by 3.6% during the fourth quarter. Capital Investment Counsel Inc now owns 5,724 shares of the medical equipment provider's stock worth $413,000 after buying an additional 200 shares during the last quarter. Institutional investors own 94.73% of the company's stock.

Remove Ads

Hologic Stock Down 1.3 %

HOLX stock traded down $0.83 during mid-day trading on Friday, reaching $60.86. The company had a trading volume of 6,509,048 shares, compared to its average volume of 1,842,488. Hologic, Inc. has a 52 week low of $59.06 and a 52 week high of $84.67. The company has a market capitalization of $13.66 billion, a price-to-earnings ratio of 19.20, a PEG ratio of 2.14 and a beta of 0.97. The company has a debt-to-equity ratio of 0.52, a current ratio of 3.49 and a quick ratio of 2.78. The stock has a 50 day simple moving average of $64.30 and a two-hundred day simple moving average of $72.59.

Hologic (NASDAQ:HOLX - Get Free Report) last issued its earnings results on Wednesday, February 5th. The medical equipment provider reported $1.03 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $1.02 by $0.01. Hologic had a net margin of 18.42% and a return on equity of 19.72%. As a group, equities analysts predict that Hologic, Inc. will post 4.28 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

A number of research analysts have recently issued reports on the stock. Stephens reissued an "overweight" rating and issued a $84.00 target price on shares of Hologic in a report on Thursday, February 6th. William Blair reiterated an "outperform" rating on shares of Hologic in a research report on Thursday, February 6th. Argus cut shares of Hologic from a "buy" rating to a "hold" rating in a research report on Monday, March 3rd. Morgan Stanley cut their price target on shares of Hologic from $84.00 to $82.00 and set an "equal weight" rating on the stock in a research report on Monday, January 13th. Finally, Evercore ISI dropped their price objective on Hologic from $76.00 to $73.00 and set an "in-line" rating on the stock in a research note on Thursday, February 6th. Eleven research analysts have rated the stock with a hold rating, six have assigned a buy rating and one has issued a strong buy rating to the company's stock. Based on data from MarketBeat, the stock currently has an average rating of "Hold" and a consensus target price of $84.62.

About Hologic

Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment. The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. It provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginosis and candida vaginitis assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays to detect SARS-CoV-2; ThinPrep System for cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth.